Description
The Finecare™ CEA Rapid Quantitative Test is designed for the quantitative determination of carcinoembryonic antigen (CEA) in human whole blood, serum, or plasma. CEA is a tumor marker used in clinical evaluation, including monitoring therapeutic response, prognosis, and possible recurrence.
Using fluorescence immunoassay technology with compatible Finecare™ FIA Systems, this test provides quantitative results in approximately 15 minutes.
Key Features
- Quantitative CEA measurement
- Fluorescence immunoassay technology
- Results in approximately 15 minutes
- Whole blood, serum, and plasma compatibility
- Supports treatment response evaluation
- Supports recurrence monitoring
Technical Specifications
| Parameter | Details |
|---|---|
| Cat. No. | W226 |
| Test Item | CEA |
| Specimen | Serum / Plasma / Whole Blood |
| Reaction Time | 15 minutes |
| Measuring Range | 1–500 ng/mL |
| Qualification | CE, NMPA |
Intended Use
For quantitative determination of carcinoembryonic antigen in human whole blood, serum, or plasma using a compatible Finecare™ FIA System. It is used as an aid in evaluating therapeutic efficiency, prognosis, and recurrence monitoring for carcinoma.
Storage and Stability
- Store at 4–30°C until the expiration date printed on the package.
- If refrigerated, allow 30 minutes to reach room temperature before testing.
- Keep the cartridge sealed until use.
- Use within one hour after opening the pouch.
